trial

Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder

NCTId NCT00892021
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Withdrawn
Enrollment 0 (actual)
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer
Primary completion 2009-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2009-05
Primary completion
2009-10
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
NSA-789

Sponsors

Wyeth is now a wholly owned subsidiary of PfizerLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE1
Primary Completion Date
2009-10
Status
WITHDRAWN
relationships
The graph out of here
drug
NSA-789
drug
lead_sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
company
indication
Schizophrenia
indication
Schizophrenia
indication